Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
RNA | US
0.18
0.38%
Healthcare
Biotechnology
30/06/2024
04/10/2024
47.30
48.00
48.61
47.08
Avidity Biosciences Inc. a biopharmaceutical company engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1 a rare monogenic muscle disease is under phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of Duchenne Muscular Dystrophy which is under phase 1/2 clinical trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy is in phase 1/2 clinical trial. Avidity Biosciences Inc. was incorporated in 2012 and is headquartered in San Diego California.
View LessPositive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Sharpe Ratio (> 1.2)
High Short-term Volatility
High 6-Month Volatility (>65%)
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
76.7%1 month
55.4%3 months
60.4%6 months
73.2%-
-
4.10
0.01
0.01
-5.72
350.37
-
-282.67M
5.59B
5.59B
-
-4.04K
-
-11.70
-28.36
9.60
12.52
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
8.40
Range1M
10.06
Range3M
12.78
Rel. volume
0.47
Price X volume
36.20M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Ionis Pharmaceuticals Inc | IONS | Biotechnology | 37.91 | 5.98B | -3.73% | n/a | 749.72% |
Blueprint Medicines Corporation | BPMC | Biotechnology | 88.61 | 5.61B | -2.37% | n/a | 231.18% |
Krystal Biotech Inc | KRYS | Biotechnology | 177.11 | 5.09B | -0.15% | 44.85 | 0.92% |
Ultragenyx Pharmaceutical Inc | RARE | Biotechnology | 53.79 | 4.96B | -3.17% | n/a | 214.27% |
Alkermes plc | ALKS | Biotechnology | 28.97 | 4.77B | -0.10% | 12.07 | 28.66% |
Corcept Therapeutics Incorporated | CORT | Biotechnology | 45.43 | 4.75B | -0.94% | 38.88 | 0.95% |
BridgeBio Pharma Inc | BBIO | Biotechnology | 25.23 | 4.74B | 0.60% | n/a | -158.23% |
ADMA Biologics Inc | ADMA | Biotechnology | 20.29 | 4.73B | 4.05% | 138.46 | 75.10% |
Madrigal Pharmaceuticals Inc | MDGL | Biotechnology | 208.41 | 4.53B | -0.35% | n/a | 13.77% |
Common Stock | IMVT | Biotechnology | 30.51 | 4.51B | 3.35% | n/a | 0.01% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Thor Industries Inc | THO | Recreational Vehicles | 108.64 | 5.75B | -0.91% | 22.26 | 27.88% |
Polaris Industries Inc | PII | Recreational Vehicles | 82.25 | 4.59B | 0.61% | 14.90 | 170.51% |
Harley-Davidson Inc | HOG | Recreational Vehicles | 34.78 | 4.58B | -4.61% | 7.97 | 218.58% |
BRP Inc | DOOO | Recreational Vehicles | 59.31 | 4.30B | 2.21% | 24.84 | 552.13% |
LCI Industries | LCII | Recreational Vehicles | 118.67 | 3.02B | -1.21% | 25.17 | 77.66% |
VeriFone Systems Inc | PAY | Building Products & Equipment | 20.8 | 2.59B | 4.58% | 76.96 | 2.10% |
HNI Corporation | HNI | Building Products & Equipment | 53.27 | 2.51B | 0.72% | 21.28 | 76.47% |
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.42 | 1.68B | 0.17% | 42.66 | 64.69% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 57.84 | 1.66B | 0.98% | 21.48 | 56.33% |
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -5.72 | 0.76 | Cheaper |
Ent. to Revenue | 350.37 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 4.10 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 60.40 | 74.67 | Par |
Debt to Equity | 0.01 | -1.82 | Expensive |
Debt to Assets | 0.01 | 0.26 | Cheaper |
Market Cap | 5.59B | 3.73B | Market Leader |